Dosage Forms

Articles

The market for biosimilars in Europe remains consistently robust, with 16 new biosimilars approved in 2018.

Roundup of European Biosimilars Approved in 2018

The company’s biosimiliar to Roche’s Avastin (bevacizumab) received a positive opinion for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Pfizer Receives Positive CHMP Opinion for Avastin Biosimilar

FDA has approved Truxima (rituximab-abbs), a biosimilar to Roche’s anti-cancer biologic, Rituxan (rituximab).

FDA Approves Celltrion and Teva’s Biosimilar to Rituxan

AbbVie will grant Pfizer license to launch a biosimilar to AbbVie’s Humira worldwide.

Pfizer Gets Global Patent License for AbbVie’s Humira

AbbVie will grant Momenta license to launch a biosimilar to AbbVie’s Humira.

AbbVie Signs Patent License with Momenta for Humira Biosimilar

The company received FDA approval for Hyrimoz (adalimumab-adaz), its biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).

Sandoz Gets FDA Approval for Humira Biosimilar

The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).

Biogen and Samsung Bioepis Launch Humira Biosimilar in Europe

Mylan announced the launch of its biosimilar to AbbVie’s Humira across major European markets.

Mylan Launches Humira Biosimilar in Europe

Amgen’s biosimilar to AbbVie’s Humira (adalimumab) is the first inflammation biosimilar from Amgen's portfolio to launch in Europe.

Amgen Launches Adalimumab Biosimilar in Europe

Novartis’ Sandoz has reached a global patent resolution for Hyrimoz (adalimumab), its biosimilar to AbbVie’s Humira (adalimumab). 

Biosimilars and Biobetters